ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      60,071.44
      1.41%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aeterna Zentaris Inc (AEZS)

      7. Aeterna Zentaris Inc (AEZS) News

      AEZS

      Aeterna Zentaris (AEZS)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AEZS
      DateTimeSourceHeadlineSymbolCompany
      01/14/20138:20AMMarketwiredMerger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With CashNASDAQ:AEZSAeterna Zentaris Inc
      01/08/20132:12PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:AEZSAeterna Zentaris Inc
      01/08/20132:12PMEdgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:AEZSAeterna Zentaris Inc
      01/02/20134:30AMZacksSPA for Aeterna Zentaris Candidate - Analyst BlogNASDAQ:AEZSAeterna Zentaris Inc
      12/31/20128:30AMMarketwiredOur Pros Knew LDK, BGCP, AEZS and YONG Would Be Top Gainers on FridayNASDAQ:AEZSAeterna Zentaris Inc
      12/28/20127:30AMPR Newswire (Canada)Aeterna Zentaris s'entend avec la FDA sur l'évaluation spéciale d'un protocole pour l'étude d'enregistrement de phase 3 su...NASDAQ:AEZSAeterna Zentaris Inc
      12/28/20127:30AMPR Newswire (Canada)Aeterna Zentaris Granted Special Protocol Assessment by the FDA for Phase 3 Registration Trial in Endometrial Cancer with AEZ...NASDAQ:AEZSAeterna Zentaris Inc
      12/28/20127:30AMPR Newswire (US)Aeterna Zentaris Granted Special Protocol Assessment by the FDA for Phase 3 Registration Trial in Endometrial Cancer with AEZ...NASDAQ:AEZSAeterna Zentaris Inc
      12/11/20127:30AMPR Newswire (US)Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretr...NASDAQ:AEZSAeterna Zentaris Inc
      12/11/20127:30AMPR Newswire (Canada)Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretr...NASDAQ:AEZSAeterna Zentaris Inc
      12/11/20127:30AMPR Newswire (Canada)Aeterna Zentaris : les données finales de phase 2 sur perifosine combiné à sorafenib démontrent que ce traitement a été...NASDAQ:AEZSAeterna Zentaris Inc
      12/04/20127:30AMPR Newswire (Canada)Aeterna Zentaris fera une présentation à l'Oppenheimer 23rd Annual Healthcare Conference à New YorkNASDAQ:AEZSAeterna Zentaris Inc
      12/04/20127:30AMPR Newswire (Canada)Aeterna Zentaris to Present at Oppenheimer 23rd Annual Healthcare Conference in New YorkNASDAQ:AEZSAeterna Zentaris Inc
      12/04/20127:30AMPR Newswire (US)Aeterna Zentaris to Present at Oppenheimer 23rd Annual Healthcare Conference in New YorkNASDAQ:AEZSAeterna Zentaris Inc
      11/26/20127:30AMPR Newswire (US)Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH MeetingNASDAQ:AEZSAeterna Zentaris Inc
      11/26/20127:30AMPR Newswire (Canada)Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH MeetingNASDAQ:AEZSAeterna Zentaris Inc
      11/26/20127:30AMPR Newswire (Canada)Aeterna Zentaris : les données finales de phase 2 sur perifosine pour le traitement de lymphomes seront présentées à l'as...NASDAQ:AEZSAeterna Zentaris Inc
      11/20/20128:20AMMarketwiredImproving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry's Success in 2012NASDAQ:AEZSAeterna Zentaris Inc
      11/19/20124:03PMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:AEZSAeterna Zentaris Inc
      11/19/20124:03PMEdgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:AEZSAeterna Zentaris Inc
      11/19/20127:30AMPR Newswire (Canada)Aeterna Zentaris: Data Demonstrate that Perifosine Combined with Temsirolimus Was Well Tolerated in Phase 1 Trial in Malignan...NASDAQ:AEZSAeterna Zentaris Inc
      11/19/20127:30AMPR Newswire (Canada)Aeterna Zentaris : selon des données de phase 1, perifosine combiné à temsirolimus a été bien toléré par des patients ...NASDAQ:AEZSAeterna Zentaris Inc
      11/19/20127:30AMPR Newswire (US)Aeterna Zentaris: Data Demonstrate that Perifosine Combined with Temsirolimus Was Well Tolerated in Phase 1 Trial in Malignan...NASDAQ:AEZSAeterna Zentaris Inc
      11/13/20124:45PMEdgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:AEZSAeterna Zentaris Inc
      11/13/20124:45PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:AEZSAeterna Zentaris Inc
      11/13/20124:42PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:AEZSAeterna Zentaris Inc
      11/13/20124:42PMEdgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:AEZSAeterna Zentaris Inc
      11/13/20124:30PMPR Newswire (Canada)Aeterna Zentaris annonce ses résultats financiers et d'exploitation du troisième trimestre 2012NASDAQ:AEZSAeterna Zentaris Inc
      11/13/20124:30PMPR Newswire (Canada)Aeterna Zentaris Reports Third Quarter 2012 Financial and Operating ResultsNASDAQ:AEZSAeterna Zentaris Inc
      11/13/20124:30PMPR Newswire (US)Aeterna Zentaris Reports Third Quarter 2012 Financial and Operating ResultsNASDAQ:AEZSAeterna Zentaris Inc
       Showing the most relevant articles for your search:NASDAQ:AEZS